<DOC>
	<DOC>NCT03086369</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.</brief_summary>
	<brief_title>A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent. If present, clinically significant or symptomatic amounts of ascites should be drained prior to Day 1. No prior line of systemic therapy for metastatic disease. Prior radiation therapy for treatment of cancer is allowed to &lt;25% of the bone marrow. Phase 2: archival tumor tissue or be willing to provide a pretreatment biopsy. Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Discontinued all previous treatments for cancer â‰¥4 weeks prior. Adequate organ function. Life expectancy of at least 3 months. Serious concomitant systemic disorder. First line treatment for metastatic pancreatic cancer. Received prior treatment with FOLFOX or FOLFIRINOX. Have known central nervous system malignancy or metastasis. Current hematologic malignancies. Participated within the last 30 days in a clinical trial. Women with a positive pregnancy test or lactating. Have endocrine pancreatic tumors or ampullary cancer. Currently enrolled in another clinical trial. History of any other cancer unless in complete remission and off treatment for a minimum of 3 years. Known allergy to nabpaclitaxel or gemcitabine or any ingredient of study drug formulations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>